The guideline, Pharmacologic Management of Newly Detected Atrial Fibrillation was developed by the American Academy of Family Physicians. It was approved by the Board of Directors in April 2017.
See the full recommendation for further details.
These recommendations are provided only as assistance for physicians making clinical decisions regarding the care of their patients. As such, they cannot substitute for the individual judgment brought to each clinical situation by the patient's family physician. As with all clinical reference resources, they reflect the best understanding of the science of medicine at the time of publication, but they should be used with the clear understanding that continued research may result in new knowledge and recommendations. These recommendations are only one element in the complex process of improving the health of America. To be effective, the recommendations must be implemented.